格卡瑞韦/哌仑他韦治疗丙型肝炎病毒与1型人类免疫缺陷病毒共感染患者的疗效与安全性:EXPEDITION-2研究
EXPEDITION-2是一项3期多中心开放标签研究,评估格卡瑞韦/哌仑他韦(300 mg/120 mg)在HCV基因1-6型/HIV-1共感染成人中的疗效与安全性,无肝硬化者治疗8周、有代偿性肝硬化者治疗12周。共纳入153例患者,SVR12率为98%(150/153;95%CI 95.8-100),无肝硬化者8周治疗组137例无病毒学失败。结论认为该方案对HCV/HIV-1共感染高效且耐受良好。
要点
- 格卡瑞韦/哌仑他韦治疗HCV/HIV-1共感染,总体SVR12率为98%(150/153;95%CI 95.8-100)。
- 无肝硬化患者治疗8周,137例中无病毒学失败。
- 4例(2.6%)发生严重不良事件,均判定与格卡瑞韦/哌仑他韦无关。
核心结论
- 格卡瑞韦/哌仑他韦用于无肝硬化患者8周、肝硬化患者12周,是HCV/HIV-1共感染的高效且耐受良好的治疗,无论基线HCV载量或既往是否接受干扰素或索磷布韦治疗。
研究设计与样本
- EXPEDITION-2为3期、多中心、开放标签研究,评估格卡瑞韦/哌仑他韦(300 mg/120 mg)在HCV基因1-6型/HIV-1共感染成人中的疗效与安全性。
- 无肝硬化患者治疗8周,代偿性肝硬化患者治疗12周。
- 患者为HCV初治或经索磷布韦、利巴韦林或干扰素治疗者,抗逆转录病毒治疗(ART)初治或稳定方案者;排除经治基因3型感染者。
- 共纳入153例患者,其中16例(10%)有肝硬化。
主要发现
- 总体SVR12率为98%(n=150/153;95%置信区间95.8-100)。
- 137例接受8周治疗的患者中无病毒学失败。
- 1例基因3型感染合并肝硬化患者发生治疗中病毒学失败。
- 4例(2.6%)发生严重不良事件,均判定与格卡瑞韦/哌仑他韦无关;治疗中断罕见(<1%)。
- 所有接受ART治疗的患者在治疗期间维持HIV-1抑制(<200 copies/mL)。
临床怎么用
- 原文结论认为,格卡瑞韦/哌仑他韦用于无肝硬化患者8周、肝硬化患者12周,是HCV/HIV-1共感染的高效且耐受良好的治疗,无论基线HCV载量或既往是否接受干扰素或索磷布韦治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Once-daily glecaprevir coformulated with pibrentasvir (glecaprevir/pibrentasvir) demonstrated high rates of sustained virologic response 12 weeks after treatment (SVR12) in patients with hepatitis C virus (HCV) genotype 1-6 infection. This phase 3 study evaluated the efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV genotype 1-6 and human immunodeficiency virus type 1 (HIV-1) coinfection, including patients with compensated cirrhosis. METHODS: EXPEDITION-2 was a phase 3, multicenter, open-label study evaluating glecaprevir/pibrentasvir (300 mg/120 mg) in HCV genotype 1-6/HIV-1-coinfected adults without and with compensated cirrhosis for 8 and 12 weeks, respectively. Patients were either HCV treatment-naive or experienced with sofosbuvir, ribavirin, or interferon, and antiretroviral therapy (ART) naive or on a stable ART regimen. Treatment-experienced genotype 3-infected patients were excluded. The primary endpoint was the SVR12 rate. RESULTS: In total, 153 patients were enrolled, including 16 (10%) with cirrhosis. The SVR12 rate was 98% (n = 150/153; 95% confidence interval, 95.8-100), with no virologic failures in 137 patients treated for 8 weeks. One genotype 3-infected patient with cirrhosis had on-treatment virologic failure. Most adverse events were mild in severity; 4 patients (2.6%) had serious adverse events, all deemed unrelated to glecaprevir/pibrentasvir. Treatment discontinuation was rare (<1%). All patients treated with ART maintained HIV-1 suppression (<200 copies/mL) during treatment. CONCLUSIONS: Glecaprevir/pibrentasvir for 8 weeks in noncirrhotic and 12 weeks in cirrhotic patients is a highly efficacious and well-tolerated treatment for HCV/HIV-1 coinfection, regardless of baseline HCV load or prior treatment with interferon or sofosbuvir. CLINICAL TRIAL REGISTRATION: NCT02738138.
引用
- Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018. PMID: 29566246. doi:10.1093/cid/ciy220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。